Quarterly ResultAug 7, 2026, 08:33 AM
bioAffinity Q2 Revenue $1.5M, Net Loss $3.4M; CyPath Lung Volume +216%
AI Summary
bioAffinity Technologies reported its second quarter 2026 financial results, with revenue increasing 19% year-over-year to $1.5 million and net loss narrowing to $3.4 million from $4.1 million. The company highlighted strong commercial momentum for its CyPath Lung diagnostic test, with test volume surging 216% compared to the prior year. Strategic milestones included progress in a longitudinal clinical trial, expansion of its pipeline to include diagnostics for asthma and COPD, and development of skin cancer therapeutics.
Key Highlights
- Q2 2026 revenue increased 19% to $1.5 million from $1.3 million in Q2 2025.
- Q2 2026 net loss was $3.4 million, compared to $4.1 million in Q2 2025.
- CyPath Lung diagnostic test volume increased 216% year-over-year in Q2 2026.
- CyPath Lung testing revenue for H1 2026 increased 159% to $835,000.
- Delivered 1,097 CyPath Lung test reports in H1 2026, up from 390 in H1 2025.
- Physician offices ordering CyPath Lung increased 122% in Q2 2026 YoY.
- Cash and cash equivalents were $2.4 million as of June 30, 2026.
- Completed a public offering in June 2026, generating $3.2 million gross proceeds.
Price Impact
More from BIAF